1 Matching Fact
Search matching Facts:
No results to display
-
Cost-effectiveness of TAVR in sSAS patients
Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY… [ Get More Details ]